Kantar Health does not operate a dedicated healthcare research practice in the GCC or wider Middle East. BioNixus is the international pharmaceutical and healthcare market research agency that fills that gap — delivering physician surveys, patient journey studies, brand tracking, hospital sales data, and market access research across Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, and Egypt since 2012.
Kantar Health is one of the world's most respected healthcare market research organisations, with strong physician survey infrastructure, treatment pathway databases, and brand tracking programmes across the United States, Western Europe, and parts of Asia-Pacific. Their National Health and Wellness Survey (NHWS), longitudinal patient panel, and specialist HCP research capabilities set a high standard for the industry.
However, Kantar Health has not established a dedicated healthcare research operation in the GCC or wider MENA region. The Kantar Group has consumer and FMCG research capability in some MENA markets — but Kantar Health's specialist pharmaceutical research services, physician panels, and treatment pathway products are not available through Kantar in Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, or Egypt.
This is not a temporary gap. It reflects a structural reality: the GCC pharmaceutical market, while growing rapidly under Vision 2030 in Saudi Arabia and equivalent national healthcare strategies across the region, has historically been served by global research firms through subcontracted local fieldwork rather than dedicated specialist operations.
BioNixus was built to fill precisely this gap.
| Capability | BioNixus | Kantar Health |
|---|---|---|
| GCC dedicated healthcare research | ✓ Direct — 12+ years, all 6 GCC countries | ✗ Not available |
| Saudi Arabia physician surveys | ✓ Verified panels, Arabic fieldwork | ✗ Not offered |
| UAE physician surveys | ✓ DHA, HAAD/DOH, MOHAP-aligned | ✗ Not offered |
| Kuwait, Qatar, Bahrain, Oman | ✓ Direct field capability | ✗ Not offered |
| Egypt healthcare research | ✓ Cairo regional office, direct operations | ✗ Not offered |
| Patient journey mapping — GCC | ✓ All major therapy areas | ✗ Not available in GCC |
| Treatment pathway studies — GCC | ✓ Diagnosis-to-treatment, switch behaviour | ✗ Not available in GCC |
| Brand tracking — GCC HCPs | ✓ Continuous or ad-hoc waves | ✗ Not available in GCC |
| Hospital sales data | ✓ Primary-source — pharmacy, procurement, physician | ✗ Not Kantar Health's core offering |
| Consumption analytics | ✓ Patient, indication, department, hospital level | ~ Limited to Western markets |
| KOL mapping — GCC | ✓ Therapy-specific, influence scoring | ✗ Not available in GCC |
| Market access research — GCC | ✓ SFDA, NUPCO, DHA, CMS Kuwait, HMC Qatar | ✗ Not available in GCC |
| Arabic-language fieldwork | ✓ Native Arabic-speaking teams | ✗ Not available |
| US office | ✓ Sheridan, Wyoming | ✓ Multiple US offices |
| UK office | ✓ London | ✓ London |
| Contract model | Project-based, no minimum | Enterprise subscriptions |
Kantar Health's core commercial offering is the quantitative physician survey. BioNixus delivers the same research product across all GCC markets with verified physician panels, Arabic-language questionnaires, and ICH-GCP compliant data collection.
Typical sample sizes range from 50 to 400 physicians per country per wave. BioNixus covers all major specialties: oncology, diabetes, cardiovascular, rare diseases, infectious disease, respiratory, neurology, dermatology, and nephrology. Turnaround from study design confirmation to final report: 3–7 weeks.
BioNixus designs and executes treatment pathway studies across GCC and MENA markets, combining physician-reported data with hospital consumption analytics and, where available, patient self-reported outcomes.
BioNixus treatment pathway studies cover the specific characteristics of GCC healthcare systems: the dual public/private sector structure, national formulary gatekeeping (NUPCO in Saudi Arabia, CMS in Kuwait, HMC in Qatar), and the cultural and linguistic factors that influence treatment adherence in MENA patient populations.
BioNixus delivers continuous and ad-hoc brand tracking programmes for pharmaceutical companies with GCC operations — measuring brand awareness, spontaneous and prompted recall, physician prescribing intent, brand imagery, and message recall across competitive therapy areas. Brand tracking waves can be fielded monthly, quarterly, or at key launch milestones.
BioNixus conducts qualitative depth interviews with key opinion leaders, hospital directors, payer decision-makers, and patients across all GCC markets. Focus groups are conducted in Arabic and English, with experienced moderators who understand the cultural context of healthcare conversations in Saudi Arabia, UAE, Kuwait, and Egypt.
BioNixus maps GCC payer landscapes — including SFDA registration pathways, NUPCO tender strategy, DHA formulary inclusion, CMS Kuwait procurement, and HMC Qatar formulary — for pharmaceutical companies preparing for regional launch or seeking to expand reimbursement access for established products.
In addition to research capabilities that parallel Kantar Health's offering, BioNixus provides primary-source hospital sales data — sourced directly from pharmacy dispensing records, hospital procurement systems, and physician prescription data — at patient, indication, department, and hospital level. This data layer is not part of Kantar Health's standard product portfolio in any market, giving BioNixus clients a more complete commercial intelligence picture.
Operating since 2012. Covers Riyadh, Jeddah, Makkah, Eastern Province across MOH hospitals, NGHA, KFSH&RC, and private groups. NUPCO tender data. SCHS-verified physician panels.
Dubai (DHA), Abu Dhabi (DOH/HAAD), Sharjah, Northern Emirates. Panels across Mediclinic, NMC Health, American Hospital Dubai, Aster DM, Cleveland Clinic Abu Dhabi, SEHA network.
Central Medical Supplies (CMS) procurement intelligence. MOH hospitals, Kuwait Cancer Control Centre, private sector including Royale Hayat, Al-Mowasat, Dar Al-Shifa.
Hamad Medical Corporation (HMC) — Hamad General Hospital, National Center for Cancer Care and Research, Sidra Medicine. Growing private sector including Aspetar and Al Ahli Hospital.
NHRA-regulated sector, Salmaniya Medical Complex, King Hamad University Hospital, private sector including Bahrain Specialist Hospital and American Mission Hospital.
Ministry of Health network across Muscat, Salalah, Sohar, Nizwa. Royal Hospital, Khoula Hospital, private sector. 10+ years of in-market fieldwork.
BioNixus MENA regional office in Cairo. 250,000+ registered physicians. Covers Cairo, Giza, Alexandria, Mansoura, Assiut, Upper Egypt with native Arabic-speaking field teams. The largest Arabic-speaking patient population in the world.
If your global insights team uses Kantar Health for physician surveys, brand tracking, and patient pathway studies in the US and Europe, your GCC affiliate cannot access the same research through Kantar Health in-region. BioNixus delivers methodologically equivalent research across all GCC markets — using comparable survey instruments, data quality standards, and reporting formats.
Pharmaceutical MENA regional headquarters, typically based in Dubai or Riyadh, require research that matches the standards their global teams expect — verified physician panels, ICH-GCP compliance, statistically robust sample frames, and analysis that can be integrated into global brand performance reporting.
Global research procurement teams that have preferred supplier agreements with Kantar Health face a decision when GCC fieldwork is required. BioNixus works alongside global preferred suppliers as the GCC specialist partner, ensuring MENA fieldwork meets the same standards as Kantar-conducted work in other regions.
Kantar Health does not have a dedicated healthcare market research operation in the GCC or wider Middle East. While the Kantar Group has a regional presence in MENA for consumer and FMCG research, Kantar Health's specialist pharmaceutical research services — physician surveys, patient journey studies, treatment pathway analysis, and brand tracking — are not available through Kantar in Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, or Egypt. BioNixus is the international healthcare and pharmaceutical market research agency that fills this gap.
BioNixus is the leading Kantar Health alternative for pharmaceutical and healthcare market research in the GCC and Middle East. Founded in 2012, BioNixus delivers quantitative physician surveys, patient journey and treatment pathway studies, brand tracking, qualitative KOL interviews, market access research, and competitive intelligence across Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, and Egypt. BioNixus operates from offices in London (UK), Sheridan Wyoming (USA), and Cairo (Egypt) — phone UK: +44 7727 666682, US: +1 888 465 5557.
International healthcare research agencies with genuine GCC coverage are limited. IQVIA has some presence through panel-modelled sales audit data. Ipsos Healthcare covers parts of the GCC through subcontractors. BioNixus is the specialist international agency with direct, in-market healthcare and pharmaceutical research capability across all six GCC countries plus Egypt — with Arabic-speaking field teams, verified physician panels, and established hospital data networks built over 12+ years.
Yes. BioNixus replicates Kantar Health's core research capabilities within the GCC context — quantitative physician surveys, patient journey and treatment pathway mapping, brand tracking and message testing, and qualitative depth interviews. BioNixus additionally provides hospital-level sales data and indication-level consumption analytics that are not typically part of Kantar Health's standard product portfolio, giving GCC pharmaceutical clients a more complete intelligence picture.
Kantar Health's global footprint has historically focused on the US, Western Europe, and Asia-Pacific. The GCC pharmaceutical market has traditionally been served by global firms through subcontracted local fieldwork rather than dedicated specialist operations. This creates a structural gap that BioNixus was built to fill — providing Kantar Health-equivalent research quality with direct GCC market knowledge, Arabic-language capability, and established regional physician panels that subcontracted fieldwork cannot replicate.
BioNixus designs and executes population-level health and wellness surveys across GCC markets, tailored to the specific disease burden, healthcare system structure, and cultural context of each country. While BioNixus does not have a pre-fielded syndicated equivalent to Kantar's NHWS for GCC (as none exists in the market), BioNixus can design bespoke patient surveys, HCP surveys, and population health studies covering all GCC countries and Egypt — fielded in Arabic and English with GCC-validated instruments.
BioNixus provides research scopes and budget estimates within 48 hours. Tell us your study objectives, target countries, and physician specialties — we will design a research programme that delivers the insight quality your global team expects, built on genuine GCC market knowledge.
Request a Scope →